Evidence map›Paper›PMID 35992634›Full record

ArticleFrontiers in sensors2022

Development of a Biosensor Based on Angiotensin-Converting Enzyme II for Severe Acute Respiratory Syndrome Coronavirus 2 Detection in Human Saliva.

Geisianny Moreira, Lisseth Casso-Hartmann, Shoumen Palit Austin Datta, Delphine Dean, Eric McLamore, Diana Vanegas

Open access · goldAbstract read
In one paragraph

Article in Frontiers in sensors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Geisianny MoreiraDepartment of Environmental Engineering and Earth Sciences, Clemson University, Clemson, SC, United States.
Lisseth Casso-HartmannDepartment of Environmental Engineering and Earth Sciences, Clemson University, Clemson, SC, United States.
Shoumen Palit Austin DattaMedical Device (MDPnP) Interoperability and Cybersecurity Labs, Biomedical Engineering Program, Department of Anesthesiology, Massachusetts General Hospital, Harvard Medical School, Cambridge, MA, United States.
Delphine DeanCenter for Innovative Medical Devices and Sensors (REDDI Lab), Clemson University, Clemson, SC, United States.
Eric McLamoreDepartment of Environmental Engineering and Earth Sciences, Clemson University, Clemson, SC, United States.
Diana VanegasDepartment of Environmental Engineering and Earth Sciences, Clemson University, Clemson, SC, United States.
Michigan State University · USClemson University · USMassachusetts Institute of Technology · US

Funding

Development of an Automated Diagnostic Platform for SARS-CoV-2 Monitoring in Vulnerable AreasU01AA029328 · NIAAA · CLEMSON UNIVERSITY · PI VANEGAS-GAMBOA, DIANA CAROLINA · 2021 to 2022
$897k
NIAAA NIH HHS U01 AA029328
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the novel coronavirus responsible for COVID-19. Infection in humans requires angiotensin-converting enzyme II (hACE2) as the point of entry for SARS-CoV-2. PCR testing is generally definitive but expensive, although it is highly sensitive and accurate. Biosensor-based monitoring could be a low-cost, accurate, and non-invasive approach to improve testing capacity. We develop a capacitive hACE2 biosensor for intact SARS-CoV-2 detection in saliva. Laser-induced graphene (LIG) electrodes were modified with platinum nanoparticles. The quality control of LIG electrodes was performed using cyclic voltammetry. Truncated hACE2 was used as a biorecognition element and attached to the electrode surface by streptavidin-biotin coupling. Biolayer interferometry was used for qualitative interaction screening of hACE2 with UV-attenuated virions. Electrochemical impedance spectroscopy (EIS) was used for signal transduction. Truncated hACE2 binds wild-type SARS-CoV-2 and its variants with greater avidity than human coronavirus (common cold virus). The limit of detection (LoD) is estimated to be 2,960 copies/ml. The detection process usually takes less than 30 min. The strength of these features makes the hACE2 biosensor a potentially low-cost approach for screening SARS-CoV-2 in non-clinical settings with high demand for rapid testing (for example, schools and airports).

Indexed as

attenuated virusbetacoronavirusbiosensinghuman ACE2LIG electrodessaliva diagnostics

Identifiers

PMID35992634
PMCPMC9386735
OpenAlexW4285085401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.